Medicenna Therapeutics Corp MDNA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MDNA is a good fit for your portfolio.
News
-
Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting
-
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
-
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
-
Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
-
Medicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
-
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting
-
Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update
-
Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
Trading Information
- Previous Close Price
- CAD 2.77
- Day Range
- CAD 2.46–2.76
- 52-Week Range
- CAD 0.22–2.89
- Bid/Ask
- CAD 2.46 / CAD 2.52
- Market Cap
- CAD 184.70 Mil
- Volume/Avg
- 174,458 / 178,041
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors, BiSKITs represents the novel platform comprised of Bifunctional SuperKine ImmunoTherapies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 17
- Website
- https://www.medicenna.com
Valuation
|
Metric
|
MDNA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 9.79 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
MDNA
Financial Strength
|
Metric
|
MDNA
|
|---|---|
Quick Ratio | 5.50 |
Current Ratio | 5.77 |
Interest Coverage | — |
Quick Ratio
MDNA
Profitability
|
Metric
|
MDNA
|
|---|---|
Return on Assets (Normalized) | −51.20% |
Return on Equity (Normalized) | −61.12% |
Return on Invested Capital (Normalized) | −66.25% |
Return on Assets
MDNA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ctfnmhxrxc | Gyyb | $567.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pyxvqjnj | Cgzqydg | $109.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Kdnpdwxgl | Zfnbpzk | $105.3 Bil | |
MRNA
| Moderna Inc | Qqwtnlgk | Bzjwn | $47.0 Bil | |
ARGX
| argenx SE ADR | Fbmlzkk | Cffd | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Mkbgszg | Drp | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Cmvgvbmcc | Tfrkgw | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zfyvrnp | Dphmhw | $15.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Txbkckwsv | Snrmlv | $12.7 Bil | |
INCY
| Incyte Corp | Zzvgbqk | Trfdjh | $12.0 Bil |